Rethinking Diabetes: A Weekly Review
Malattie Metaboliche e Diabetologia
Exercise, Insulin Delivery, and GLP-1 Advances in Diabetes Care
This episode explores cutting-edge research on exercise management in diabetes, innovative insulin delivery systems, and the expanding therapeutic potential of GLP-1 receptor agonists, featuring insights from leading diabetes researchers.
Bibliography
1. Exercise-induced hypoglycaemia in type 1 diabetes.
Authors: Cockcroft EJ, Narendran P, Andrews RC
Journal: Experimental physiology, 2020 Apr
PMID: 31785115
DOI: 10.1113/EP088219
2. Effects of aerobic, resistance, and combined exercise on metabolic syndrome parameters and cardiovascular risk factors: a systematic review and network meta-analysis.
Authors: Liang M, Pan Y, Zhong T, et al.
Journal: Reviews in cardiovascular medicine, 2021 Dec 22
PMID: 34957791
DOI: 10.31083/j.rcm2204156
3. Patch Pumps for Insulin.
Authors: Ginsberg BH
Journal: Journal of diabetes science and technology, 2019 Jan
PMID: 30070604
DOI: 10.1177/1932296818786513
4. GLP-1 Receptor Agonists: Beyond Their Pancreatic Effects.
Authors: Zhao X, Wang M, Wen Z, et al.
Journal: Frontiers in endocrinology, 2021
PMID: 34497589
DOI: 10.3389/fendo.2021.721135
5. Sequential anticoagulation with LMWH and DOACs in cirrhotic portal vein thrombosis.
Authors: Onay M, Heilani M, Gulia C, et al.
Journal: Clinics and research in hepatology and gastroenterology, 2026 Apr
PMID: 41740719
DOI: 10.1016/j.clinre.2026.102792
6. Expert consensus for the diagnosis and treatment of patients with hyperuricemia and high cardiovascular risk: 2025 update.
Authors: Johnson R, Gruev I, Yotov Y, et al.
Journal: European journal of internal medicine, 2026 Apr
PMID: 41786537
DOI: 10.1016/j.ejim.2026.106727
7. GLP-1 receptor agonists in the treatment of type 2 diabetes - state-of-the-art.
Authors: Nauck MA, Quast DR, Wefers J, et al.
Journal: Molecular metabolism, 2021 Apr
PMID: 33068776
DOI: 10.1016/j.molmet.2020.101102
8. Accuracy of glutamic acid decarboxylase antibodies for the identification of adult-onset type 1 diabetes mellitus: a systematic review and meta-analysis.
Authors: Shao MM, Scheideman AF, Zhou AM, et al.
Journal: Frontiers in endocrinology, 2026
PMID: 41987896
DOI: 10.3389/fendo.2026.1771950
9. Cardiovascular and kidney outcomes with finerenone in patients with type 2 diabetes and chronic kidney disease: the FIDELITY pooled analysis.
Authors: Agarwal R, Filippatos G, Pitt B, et al.
Journal: European heart journal, 2022 Feb 10
PMID: 35023547
DOI: 10.1093/eurheartj/ehab777
10. Acute interleukin-1β antagonism decreases systemic inflammation, increases GLP-1 release, and modulates insulin secretion in individuals with prediabetes.
Authors: Fischer JS, Hepprich M, Cattaneo M, et al.
Journal: American journal of physiology. Endocrinology and metabolism, 2026 Apr 1
PMID: 41778408
DOI: 10.1152/ajpendo.00527.2025
Authors: Cockcroft EJ, Narendran P, Andrews RC
Journal: Experimental physiology, 2020 Apr
PMID: 31785115
DOI: 10.1113/EP088219
2. Effects of aerobic, resistance, and combined exercise on metabolic syndrome parameters and cardiovascular risk factors: a systematic review and network meta-analysis.
Authors: Liang M, Pan Y, Zhong T, et al.
Journal: Reviews in cardiovascular medicine, 2021 Dec 22
PMID: 34957791
DOI: 10.31083/j.rcm2204156
3. Patch Pumps for Insulin.
Authors: Ginsberg BH
Journal: Journal of diabetes science and technology, 2019 Jan
PMID: 30070604
DOI: 10.1177/1932296818786513
4. GLP-1 Receptor Agonists: Beyond Their Pancreatic Effects.
Authors: Zhao X, Wang M, Wen Z, et al.
Journal: Frontiers in endocrinology, 2021
PMID: 34497589
DOI: 10.3389/fendo.2021.721135
5. Sequential anticoagulation with LMWH and DOACs in cirrhotic portal vein thrombosis.
Authors: Onay M, Heilani M, Gulia C, et al.
Journal: Clinics and research in hepatology and gastroenterology, 2026 Apr
PMID: 41740719
DOI: 10.1016/j.clinre.2026.102792
6. Expert consensus for the diagnosis and treatment of patients with hyperuricemia and high cardiovascular risk: 2025 update.
Authors: Johnson R, Gruev I, Yotov Y, et al.
Journal: European journal of internal medicine, 2026 Apr
PMID: 41786537
DOI: 10.1016/j.ejim.2026.106727
7. GLP-1 receptor agonists in the treatment of type 2 diabetes - state-of-the-art.
Authors: Nauck MA, Quast DR, Wefers J, et al.
Journal: Molecular metabolism, 2021 Apr
PMID: 33068776
DOI: 10.1016/j.molmet.2020.101102
8. Accuracy of glutamic acid decarboxylase antibodies for the identification of adult-onset type 1 diabetes mellitus: a systematic review and meta-analysis.
Authors: Shao MM, Scheideman AF, Zhou AM, et al.
Journal: Frontiers in endocrinology, 2026
PMID: 41987896
DOI: 10.3389/fendo.2026.1771950
9. Cardiovascular and kidney outcomes with finerenone in patients with type 2 diabetes and chronic kidney disease: the FIDELITY pooled analysis.
Authors: Agarwal R, Filippatos G, Pitt B, et al.
Journal: European heart journal, 2022 Feb 10
PMID: 35023547
DOI: 10.1093/eurheartj/ehab777
10. Acute interleukin-1β antagonism decreases systemic inflammation, increases GLP-1 release, and modulates insulin secretion in individuals with prediabetes.
Authors: Fischer JS, Hepprich M, Cattaneo M, et al.
Journal: American journal of physiology. Endocrinology and metabolism, 2026 Apr 1
PMID: 41778408
DOI: 10.1152/ajpendo.00527.2025
